Session Type: Abstract Submissions (ACR)
Background/Purpose: The CCR6-CCL20–mediated migration of Th17 cells to inflamed tissues may represent an important mechanism in the etiology of rheumatoid arthritis (RA). The CCR6 SNP rs3093023 is associated with RA disease risk. Variation in the CCR6 locus has been found to affect CCR6 expression and influence the IL17 serum concentration in RA patients (1). Importantly, an analysis of disease risk stratified by gender revealed opposing effects in Asian subjects: Specifically a CCR6SNP (rs3093024), which is in almost complete linkage disequilibrium with rs3093023, was associated with an increased risk of RA in women, but appeared to have a protective effect in men (2). We set out to determine whether variation in estrogen levels might influence the expression of CCR6 and other IL-17 pathway related genes. Furthermore, we aimed to clarify if such estrogen dependent regulation might be influenced by the presence of the variant CCR6genotype that is associated with RA disease risk in Europeans.
Methods: We genome-wide genotyped human lymphoblastoid cells using the Illumina 550K and 510S SNP BeadChip and the Affymetrix SNP array 6.0. We then cultured eight LCLs homozygous for the wild-type (WT) SNP rs3093023 sequence and eight LCLs homozygous for the variant (V) allele with increasing concentrations of estradiol (E2). Expression of CCR6, CCL20, IL17A and IL17RA mRNA was measured by qPCR. We then performed siRNA knockdown experiments for CCR6 to explore the downstream effects. To predict putative estrogen receptor binding sites in the CCR6gene, we queried the TRANSFEC database. The functional relevance of putative binding sites was confirmed using ChIP assays.
Results: The basal expression levels of CCR6, CCL20, IL17A and IL17RA showed no differences when comparing cell lines with CCR6 WT versus V genotypes. Knockdown of CCR6 resulted in upregulation of CCL20 and IL-17A, but downregulation of IL-17RA expression. Treatment with E2 for 24 hours resulted in a significant increase in CCR6 expression in a dose-dependent manner, but only in cells with the V allele. CCL20, IL-17A and IL17 RA expression was also SNP-dependent: in cells with the variant genotype, E2 treatment resulted in higher IL-17RA expression. Conversely, CCL20 and IL-17A expression decreased with estrogen treatment only in cells homozygous for the V allele. The TRANSFEC database predicted the presence of two estrogen response elements in the CCR6intronic region flanking the rs3093023 SNP. Chip essays demonstrated increased binding of estrogen receptor alpha when the V allele was present.
Conclusion: Our results indicate that a CCR6variant, which is associated with RA disease risk, can modulate the CCR6/CCL20/IL-17 axis in an estrogen-dependent manner. Enhanced binding of estrogen receptor alpha to the variant CCR6 genotype may contribute to the mechanism underlying this observation. Such a genomic link between variation in sex hormone levels and variation in cytokine/chemokine expression may provide new insights into the gender differences in RA prevalence and prognosis.
References : (1) Kochi Y, et al. Nat Genet 2010 (2) Teng E et al.: DNA Cell Biol. 2012
M. F. Ho,
R. M. Weinshilboum,
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-rheumatoid-arthritis-risk-locus-ccr6-and-its-snp-dependent-response-to-estrogen-a-possible-genomic-link-between-sex-hormones-and-the-il-17-inflammatory-pathway/